Eris Lifesciences Limited (ERIS.BO)
INR 1321.05
(3.6%)
INR 1321.05
(3.6%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 3.91 Billion INR | 2.57% |
| 2022 | 3.82 Billion INR | -5.9% |
| 2021 | 4.06 Billion INR | 14.35% |
| 2020 | 3.55 Billion INR | 19.78% |
| 2019 | 2.96 Billion INR | 1.96% |
| 2018 | 2.9 Billion INR | -1.13% |
| 2017 | 2.94 Billion INR | 19.17% |
| 2016 | 2.46 Billion INR | 84.76% |
| 2015 | 1.33 Billion INR | 49.68% |
| 2014 | 892.34 Million INR | 26.72% |
| 2013 | 704.19 Million INR | 21.0% |
| 2012 | 581.98 Million INR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 915.9 Million INR | 10.11% |
| 2024 Q1 | 831.8 Million INR | 17.22% |
| 2023 Q2 | 1.23 Billion INR | 30.12% |
| 2023 Q4 | 709.62 Million INR | -30.93% |
| 2023 FY | 3.91 Billion INR | 2.57% |
| 2023 Q1 | 948.6 Million INR | 45.01% |
| 2023 Q3 | 1.02 Billion INR | -16.77% |
| 2022 Q4 | 654.18 Million INR | -35.78% |
| 2022 FY | 3.82 Billion INR | -5.9% |
| 2022 Q3 | 1.01 Billion INR | -15.33% |
| 2022 Q2 | 1.2 Billion INR | 27.2% |
| 2022 Q1 | 945.77 Million INR | 17.79% |
| 2021 Q1 | 1.06 Billion INR | 56.28% |
| 2021 Q3 | 1 Billion INR | -14.89% |
| 2021 FY | 4.06 Billion INR | 14.35% |
| 2021 Q2 | 1.18 Billion INR | 11.0% |
| 2021 Q4 | 802.96 Million INR | -20.31% |
| 2020 Q4 | 682.47 Million INR | -24.3% |
| 2020 Q1 | 890.18 Million INR | 58.19% |
| 2020 Q2 | 1.07 Billion INR | 21.01% |
| 2020 Q3 | 901.5 Million INR | -16.31% |
| 2020 FY | 3.55 Billion INR | 19.78% |
| 2019 Q3 | 634.69 Million INR | -31.54% |
| 2019 FY | 2.96 Billion INR | 1.96% |
| 2019 Q4 | 562.72 Million INR | -11.34% |
| 2019 Q2 | 927.11 Million INR | 10.31% |
| 2019 Q1 | 840.45 Million INR | 55.39% |
| 2018 Q3 | 801.38 Million INR | -6.07% |
| 2018 FY | 2.9 Billion INR | -1.13% |
| 2018 Q4 | 540.87 Million INR | -32.51% |
| 2018 Q2 | 853.2 Million INR | 19.75% |
| 2018 Q1 | 712.51 Million INR | 27.72% |
| 2017 Q4 | 557.87 Million INR | -25.23% |
| 2017 FY | 2.94 Billion INR | 19.17% |
| 2017 Q1 | 708.37 Million INR | 66.62% |
| 2017 Q2 | 928.68 Million INR | 31.1% |
| 2017 Q3 | 746.13 Million INR | -19.66% |
| 2016 Q3 | 681.04 Million INR | -1.33% |
| 2016 FY | 2.46 Billion INR | 84.76% |
| 2016 Q4 | 425.13 Million INR | -37.58% |
| 2016 Q2 | 690.22 Million INR | 10.54% |
| 2016 Q1 | 624.39 Million INR | 0.0% |
| 2015 FY | 1.33 Billion INR | 49.68% |
| 2014 FY | 892.34 Million INR | 26.72% |
| 2013 FY | 704.19 Million INR | 21.0% |
| 2012 FY | 581.98 Million INR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 6.15 Billion INR | 36.348% |
| Aurobindo Pharma Limited | 31.72 Billion INR | 87.646% |
| Glenmark Life Sciences Limited | 4.7 Billion INR | 16.757% |
| Granules India Limited | 4.05 Billion INR | 3.288% |
| Indoco Remedies Limited | 984.6 Million INR | -298.114% |
| Achyut Healthcare Limited | 5.73 Million INR | -68285.031% |
| Ajanta Pharma Limited | 8.16 Billion INR | 51.973% |
| Alkem Laboratories Limited | 17.95 Billion INR | 78.172% |
| Alpa Laboratories Limited | 167.76 Million INR | -2236.5% |
| Brooks Laboratories Limited | -195.91 Million INR | 2100.74% |
| AstraZeneca Pharma India Limited | 1.61 Billion INR | -142.699% |
| Bajaj HealthCare Limited | -837.93 Million INR | 567.799% |
| Bliss GVS Pharma Limited | 754.54 Million INR | -419.499% |
| Dr. Reddy's Laboratories Limited | 55.68 Billion INR | 92.961% |
| FDC Limited | 3.05 Billion INR | -28.425% |
| Glenmark Pharmaceuticals Limited | -15.01 Billion INR | 126.103% |
| Gufic Biosciences Limited | 861.35 Million INR | -355.077% |
| Ind-Swift Laboratories Limited | 4.2 Billion INR | 6.884% |
| Ipca Laboratories Limited | 5.47 Billion INR | 28.385% |
| Jagsonpal Pharmaceuticals Limited | 224.63 Million INR | -1645.016% |
| Krebs Biochemicals & Industries Limited | -197.28 Million INR | 2086.897% |
| Lasa Supergenerics Limited | -217.3 Million INR | 1903.83% |
| Laurus Labs Limited | 1.6 Billion INR | -144.15% |
| Lupin Limited | 19.14 Billion INR | 79.525% |
| Mankind Pharma Limited | 19.12 Billion INR | 79.508% |
| Medicamen Biotech Limited | 109.31 Million INR | -3485.976% |
| Medico Remedies Limited | 82.9 Million INR | -4627.87% |
| Megasoft Limited | -127.46 Million INR | 3175.197% |
| NATCO Pharma Limited | 13.88 Billion INR | 71.765% |
| Piramal Pharma Limited | 178.2 Million INR | -2099.68% |
| RPG Life Sciences Limited | 876.6 Million INR | -347.163% |
| Sigachi Industries Limited | 571.8 Million INR | -585.522% |
| Sun Pharmaceutical Industries Limited | 95.76 Billion INR | 95.907% |
| Suven Pharmaceuticals Limited | 3 Billion INR | -30.539% |
| Syncom Formulations (India) Limited | 253.14 Million INR | -1448.471% |
| Unichem Laboratories Limited | -704.74 Million INR | 656.207% |
| Wanbury Limited | 559.56 Million INR | -600.516% |
| Windlas Biotech Limited | 581.87 Million INR | -573.661% |
| ZIM Laboratories Limited | 172.46 Million INR | -2172.84% |
| Zydus Lifesciences Limited | 38.59 Billion INR | 89.844% |
| Sun Pharma Advanced Research Company Limited | -3.87 Billion INR | 201.232% |
| Divi's Laboratories Limited | 16 Billion INR | 75.501% |
| Hester Biosciences Limited | 188.89 Million INR | -1975.192% |
| Procter & Gamble Health Limited | 2 Billion INR | -95.036% |
| Amrutanjan Health Care Limited | 449.72 Million INR | -771.604% |
| Bal Pharma Limited | 73.92 Million INR | -5202.657% |
| Strides Pharma Science Limited | -706.14 Million INR | 655.107% |
| Venus Remedies Limited | 284.9 Million INR | -1275.823% |
| Aarti Pharmalabs Limited | 2.16 Billion INR | -80.719% |
| Nectar Lifesciences Limited | 49.95 Million INR | -7747.508% |
| Shilpa Medicare Limited | 318.74 Million INR | -1129.781% |
| Aarti Drugs Limited | 1.71 Billion INR | -128.671% |
| IOL Chemicals and Pharmaceuticals Limited | 1.34 Billion INR | -191.589% |
| Suven Life Sciences Limited | -1.05 Billion INR | 473.046% |
| Ind-Swift Limited | 142.31 Million INR | -2654.372% |
| Valiant Laboratories Limited | 3.19 Million INR | -122547.997% |
| J. B. Chemicals & Pharmaceuticals Limited | 5.52 Billion INR | 29.069% |
| Solara Active Pharma Sciences Limited | -5.67 Billion INR | 169.085% |
| Themis Medicare Limited | 435.23 Million INR | -800.618% |
| Hikal Limited | 696.02 Million INR | -463.178% |
| Torrent Pharmaceuticals Limited | 16.56 Billion INR | 76.335% |
| Sequent Scientific Limited | -358.69 Million INR | 1192.818% |
| Novartis India Limited | 851.9 Million INR | -360.128% |
| Wockhardt Limited | -4.63 Billion INR | 184.662% |
| Jubilant Pharmova Limited | 771 Million INR | -408.409% |
| Biofil Chemicals and Pharmaceuticals Limited | 7.09 Million INR | -55171.151% |
| Neuland Laboratories Limited | 3 Billion INR | -30.627% |
| Morepen Laboratories Limited | 961.59 Million INR | -307.637% |
| Kilitch Drugs (India) Limited | 146.01 Million INR | -2584.558% |
| Mangalam Drugs & Organics Limited | -90.71 Million INR | 4420.943% |